PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31001934-1	2019	BACKGROUND: Removal of uremic toxins such as indoxyl sulfate by AST-120 is known to improve renal function and delay the initiation of dialysis in patients with advanced chronic kidney disease.	Indican	45-60	solute carrier family 17 member 5	Homo sapiens	64-67	
33658826-13	2021	Plasma levels of blood urea nitrogen, creatinine, indoxyl sulfate, IL-1beta and renal tubular injury were increased in mice after renal I/R and were decreased by AST-120 treatment.	Indican	50-65	solute carrier family 17 member 5	Homo sapiens	162-165	
33484425-11	2021	CONCLUSIONS: The present meta-analysis demonstrated that prebiotics, synbiotics, and AST-120 can effectively reduce both serum indoxyl sulfate and p-cresyl sulfate in CKD patients when compared with placebo.	Indican	127-142	solute carrier family 17 member 5	Homo sapiens	85-88	
28392999-7	2017	At one year, the AST-120-induced decrease in the serum indoxyl sulfate concentration inversely correlated with the occurrence of composite primary outcomes: second tertile HR 1.59, 95% CI 0.82 to 3.07, P = 0.17; third tertile HR 2.11, 95% CI 1.07 to 4.17, P = 0.031.	Indican	55-70	solute carrier family 17 member 5	Homo sapiens	17-20	
28392999-10	2017	Reduction of the serum indoxyl sulfate level may be used to identify patients who would benefit from AST-120 administration.	Indican	23-38	solute carrier family 17 member 5	Homo sapiens	101-104	
24576840-5	2014	RESULTS: AST-120 significantly decreased both the total and free forms of indoxyl sulfate and p-cresol sulfate ranging from 21.9 to 58.3%.	Indican	74-89	solute carrier family 17 member 5	Homo sapiens	9-12	
24576840-8	2014	CONCLUSIONS: AST-120 effectively decreased indoxyl sulfate and p-cresol sulfate levels in both total and free forms.	Indican	43-58	solute carrier family 17 member 5	Homo sapiens	13-16	
23362306-0	2013	Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease.	Indican	13-28	solute carrier family 17 member 5	Homo sapiens	32-35	
20797565-2	2010	The oral sorbent AST-120 reduces the serum levels of indoxyl sulfate in CKD patients by adsorbing indole, a precursor of indoxyl sulfate, in the intestine, and thereby stimulating its excretion in feces.	Indican	121-136	solute carrier family 17 member 5	Homo sapiens	17-20	
20797565-11	2010	Therefore, AST-120 may ameliorate the progression of cardiovascular disease as well as of CKD by removing indoxyl sulfate.	Indican	106-121	solute carrier family 17 member 5	Homo sapiens	11-14	
19378798-1	2009	BACKGROUND: Oral adsorbent AST-120 reduces uremic toxins, such as indoxyl sulfate, and retards the progression of chronic kidney disease (CKD).	Indican	66-81	solute carrier family 17 member 5	Homo sapiens	27-30	
9387112-2	1997	In this study we determined if a low-protein diet or oral sorbent (AST-120) could reduce the serum and urine levels of indoxyl sulfate in 5/6-nephrectomized uremic rats and undialyzed uremic patients.	Indican	119-134	solute carrier family 17 member 5	Homo sapiens	67-70	
9387112-4	1997	The serum and urine levels of indoxyl sulfate dramatically decreased 1-2 days after fasting or AST-120 treatment.	Indican	30-45	solute carrier family 17 member 5	Homo sapiens	95-98	
9387112-7	1997	Administration of AST-120 significantly decreased serum and urine levels of indoxyl sulfate in 22 undialyzed uremic patients.	Indican	76-91	solute carrier family 17 member 5	Homo sapiens	18-21	
9387112-8	1997	In conclusion, a low-protein diet or AST-120 reduced the serum and urine levels of indoxyl sulfate, a stimulating factor for glomerular sclerosis, in both uremic rats and undialyzed uremic patients.	Indican	83-98	solute carrier family 17 member 5	Homo sapiens	37-40	
30336612-0	2018	AST-120 Reduces Neuroinflammation Induced by Indoxyl Sulfate in Glial Cells.	Indican	45-60	solute carrier family 17 member 5	Homo sapiens	0-3	
27990791-5	2017	The carbon adsorbent AST-120 might be useful to delay the progression of not only CKD but also CVD, osteodystrophy, and sarcopenia by adsorbing its precursor, indole, in the intestines, and consequently reducing the serum levels of indoxyl sulfate.	Indican	232-247	solute carrier family 17 member 5	Homo sapiens	21-24	
20870466-5	2010	Indoxyl sulfate was the first principal serum metabolite, which could differentiate CRF from both normal and AST-120-administered CRF rats, followed by hippuric acid, phenyl sulfate and 4-ethylphenyl sulfate.	Indican	0-15	solute carrier family 17 member 5	Homo sapiens	109-112	
20870466-8	2010	In conclusion, indoxyl sulfate is the best indicator of the effect of AST-120 in CRF rats.	Indican	15-30	solute carrier family 17 member 5	Homo sapiens	70-73	
20797565-2	2010	The oral sorbent AST-120 reduces the serum levels of indoxyl sulfate in CKD patients by adsorbing indole, a precursor of indoxyl sulfate, in the intestine, and thereby stimulating its excretion in feces.	Indican	53-68	solute carrier family 17 member 5	Homo sapiens	17-20	
16564934-5	2006	RESULTS: AST-120 decreased serum indoxyl sulfate levels in a dose-dependent fashion.	Indican	33-48	solute carrier family 17 member 5	Homo sapiens	9-12	
9350673-2	1997	In the present study, we determined whether an oral adsorbent (AST-120) could reduce the serum and urine levels of indoxyl sulfate and suppress the progression of chronic renal failure (CRF) in undialyzed uremic patients.	Indican	115-130	solute carrier family 17 member 5	Homo sapiens	63-66	
9350673-5	1997	Administration of AST-120 significantly decreased the serum and urine levels of indoxyl sulfate, and tended to improve the slope of the 1/SCr-time plot in the CRF patients.	Indican	80-95	solute carrier family 17 member 5	Homo sapiens	18-21	
9350673-6	1997	Among the patients in whom urinary excretion of indoxyl sulfate was reduced by AST-120, the oral adsorbent significantly improved the slope of the 1/SCr-time plot.	Indican	48-63	solute carrier family 17 member 5	Homo sapiens	79-82